o(6)-benzylguanine has been researched along with Brain Neoplasms in 30 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 9.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 9.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 7.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 5.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 5.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "Resistance to temozolomide (TMZ) based chemotherapy in glioblastoma multiforme (GBM) has been attributed to the upregulation of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.80 | Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ( Chiarelli, PA; Ellenbogen, RG; Fang, C; Hatzinger, SJ; Kievit, FM; Silber, JR; Stephen, ZR; Veiseh, O; Wang, K; Zhang, M, 2014) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 3.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| " Single-dose temozolomide at five dosage levels (267, 355, 472, 628, and 835 mg/m(2)) was given at least 6 h after completion of O(6)-benzylguanine bolus." | 2.73 | Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ( Boyett, JM; Broniscer, A; Danks, MK; Friedman, HS; Gajjar, A; Goldman, S; Gururangan, S; Kun, LE; MacDonald, TJ; Packer, RJ; Poussaint, TY; Stewart, CF; Wallace, D, 2007) |
| "To report the results of the first pharmacokinetic study in pediatric patients of O(6)-benzylguanine (O(6)BG), which irreversibly inactivates the DNA repair protein alkylguanine-alkyltransferase, thus enhancing the cytotoxicity of nitrosoureas." | 2.71 | Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ( Adams, D; Aleksic, A; Berg, S; Bernstein, M; Blaney, S; Neville, K; Thompson, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (33.33) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 4 (13.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A | 1 |
| Henderson, FC | 1 |
| Alshareef, M | 1 |
| Porto, GBF | 1 |
| Kanginakudru, I | 1 |
| Infinger, LK | 1 |
| Vandergrift, WA | 1 |
| Lindhorst, SM | 1 |
| Varma, AK | 1 |
| Patel, SJ | 1 |
| Cachia, D | 1 |
| Kramer, B | 1 |
| Singh, R | 1 |
| Wischusen, J | 1 |
| Dent, R | 1 |
| Rush, A | 1 |
| Middlemiss, S | 1 |
| Ching, YW | 1 |
| Alexander, IE | 1 |
| McCowage, G | 1 |
| Adair, JE | 1 |
| Johnston, SK | 1 |
| Mrugala, MM | 1 |
| Beard, BC | 1 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Hawkins-Daarud, A | 1 |
| Gori, JL | 1 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 1 |
| Rockne, RC | 1 |
| Storer, BE | 1 |
| Rockhill, JK | 1 |
| Swanson, KR | 1 |
| Kiem, HP | 1 |
| Stephen, ZR | 1 |
| Kievit, FM | 1 |
| Veiseh, O | 1 |
| Chiarelli, PA | 1 |
| Fang, C | 1 |
| Wang, K | 1 |
| Hatzinger, SJ | 1 |
| Ellenbogen, RG | 1 |
| Silber, JR | 2 |
| Zhang, M | 1 |
| Liu, C | 1 |
| Yao, S | 1 |
| Li, X | 1 |
| Wang, F | 1 |
| Jiang, Y | 1 |
| Juillerat-Jeanneret, L | 1 |
| Bernasconi, CC | 1 |
| Bricod, C | 1 |
| Gros, S | 1 |
| Trepey, S | 1 |
| Benhattar, J | 1 |
| Janzer, RC | 1 |
| Quinn, JA | 6 |
| Jiang, SX | 4 |
| Carter, J | 1 |
| Reardon, DA | 6 |
| Desjardins, A | 5 |
| Vredenburgh, JJ | 4 |
| Rich, JN | 4 |
| Gururangan, S | 7 |
| Friedman, AH | 6 |
| Bigner, DD | 8 |
| Sampson, JH | 6 |
| McLendon, RE | 8 |
| Herndon, JE | 7 |
| Threatt, S | 1 |
| Friedman, HS | 11 |
| Walker, A | 2 |
| Kreklau, EL | 2 |
| Pollok, KE | 1 |
| Bailey, BJ | 1 |
| Liu, N | 1 |
| Hartwell, JR | 1 |
| Williams, DA | 2 |
| Erickson, LC | 2 |
| Neville, K | 1 |
| Blaney, S | 1 |
| Bernstein, M | 1 |
| Thompson, P | 1 |
| Adams, D | 1 |
| Aleksic, A | 1 |
| Berg, S | 1 |
| Bacolod, MD | 1 |
| Johnson, SP | 1 |
| Pegg, AE | 7 |
| Dolan, ME | 10 |
| Moschel, RC | 7 |
| Bullock, NS | 1 |
| Fang, Q | 1 |
| Colvin, OM | 2 |
| Modrich, P | 1 |
| Weingart, J | 3 |
| Brem, H | 2 |
| Delaney, SM | 2 |
| Vredenburgh, J | 1 |
| Rich, J | 2 |
| Birch, R | 1 |
| Provenzale, JM | 2 |
| Dancey, JE | 1 |
| Maxwell, J | 1 |
| Tourt-Uhlig, S | 2 |
| Koch, D | 1 |
| Hundsberger, T | 1 |
| Boor, S | 1 |
| Kaina, B | 1 |
| Chen, CC | 1 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Rosenblum, ML | 1 |
| Olivi, A | 1 |
| Judy, K | 1 |
| Tatter, SB | 1 |
| Broniscer, A | 1 |
| MacDonald, TJ | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Stewart, CF | 1 |
| Wallace, D | 1 |
| Danks, MK | 1 |
| Poussaint, TY | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Gajjar, A | 1 |
| Mineura, K | 3 |
| Izumi, I | 2 |
| Watanabe, K | 2 |
| Kowada, M | 3 |
| Kohda, K | 3 |
| Ikenaga, M | 2 |
| Koyama, K | 1 |
| Terashima, I | 2 |
| Felker, GM | 1 |
| Schold, C | 1 |
| Sarkar, A | 1 |
| Gonzalez, GG | 1 |
| Marton, LJ | 1 |
| Deen, DF | 1 |
| Kurpad, SN | 1 |
| Archer, GE | 1 |
| Fukuchi, M | 1 |
| Bobola, MS | 1 |
| Tseng, SH | 1 |
| Blank, A | 1 |
| Berger, MS | 1 |
| Kokkinakis, DM | 1 |
| Pluda, J | 2 |
| Cokgor, I | 1 |
| Haglund, MM | 2 |
| Ashley, DM | 1 |
| Kerby, T | 1 |
| Schold, SC | 1 |
| Kurpad, C | 1 |
| Rhines, LD | 1 |
| Sampath, P | 1 |
| Tyler, BM | 1 |
| Delaney, S | 1 |
| Kaplan, R | 1 |
| Stine, L | 1 |
| Mitchell, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme[NCT00362921] | Phase 2 | 52 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
12 trials available for o(6)-benzylguanine and Brain Neoplasms
| Article | Year |
|---|---|
Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Topics: Brain Neoplasms; Child; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; | 2018 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Central Nervous System | 2004 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Topics: Adult; Aged; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Guanine; Humans; Middle Aged; O(6)-Me | 1998 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
18 other studies available for o(6)-benzylguanine and Brain Neoplasms
| Article | Year |
|---|---|
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors.
Topics: Animals; Brain Neoplasms; Glioblastoma; Guanine; Magnetic Resonance Imaging; Magnetics; Mice; Mice, | 2014 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylatio | 2008 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Deoxyguanosine; Drug Resistanc | 2004 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Basal Ganglia; Brain Neoplasms; Cell Count; | 1994 |
Enhancing effect of O6-alkylguanine derivatives on chloroethylnitrosourea cytotoxicity toward tumor cells.
Topics: Animals; Brain Neoplasms; Cell Survival; Drug Synergism; Guanine; HeLa Cells; Humans; Nimustine; Rat | 1994 |
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Drug Synergism | 1993 |
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Topics: Biogenic Polyamines; Brain Neoplasms; Carmustine; Cell Hypoxia; Combined Modality Therapy; Drug Resi | 1993 |
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 1997 |
[Study on potentiation of nitrosourea-cytotoxicity by DNA repair enzyme inhibitors in human brain tumor cells].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Drug Resis | 1997 |
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; | 1996 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Cricetinae; Dose-Response Relationship, Drug; Female; Glioma; Guanine; Hum | 1990 |